U.S. Markets closed

Should You Buy Depomed Inc (NASDAQ:DEPO)?

David Rizzo

Depomed Inc (NASDAQ:DEPO), a pharmaceuticals company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highs of $8.67 and falling to the lows of $6.16. This high level of volatility gives investors the opportunity to enter into the stock, and potentially buy at an artificially low price. A question to answer is whether Depomed’s current trading price of $6.67 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Depomed’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change. View our latest analysis for Depomed

What is Depomed worth?

Great news for investors – Depomed is still trading at a fairly cheap price. According to my valuation, the intrinsic value for the stock is $11.75, which is above what the market is valuing the company at the moment. This indicates a potential opportunity to buy low. Although, there may be another chance to buy again in the future. This is because Depomed’s beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, the company’s shares will likely fall by more than the rest of the market, providing a prime buying opportunity.

What does the future of Depomed look like?

NasdaqGS:DEPO Future Profit Feb 13th 18

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company’s future expectations. With profit expected to grow by 87.39% over the next couple of years, the future seems bright for Depomed. It looks like higher cash flows is on the cards for the stock, which should feed into a higher share valuation.

What this means for you:

Are you a shareholder? Since DEPO is currently undervalued, it may be a great time to increase your holdings in the stock. With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as financial health to consider, which could explain the current undervaluation.

Are you a potential investor? If you’ve been keeping an eye on DEPO for a while, now might be the time to make a leap. Its prosperous future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy DEPO. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed buy.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Depomed. You can find everything you need to know about Depomed in the latest infographic research report. If you are no longer interested in Depomed, you can use our free platform to see my list of over 50 other stocks with a high growth potential.


To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.